NasdaqGS:DAWNBiotechsWe're Hopeful That Day One Biopharmaceuticals (NASDAQ:DAWN) Will Use Its Cash WiselyMarch 18, 2024Just because a business does not make any money, does not mean that the stock will go down. For example, although...
NasdaqCM:EXASBiotechsExact Sciences Corporation (NASDAQ:EXAS): Is Breakeven Near?March 18, 2024With the business potentially at an important milestone, we thought we'd take a closer look at Exact Sciences...
NasdaqGM:SPRYBiotechsWe're Not Very Worried About ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn RateMarch 18, 2024Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
NasdaqGS:IONSBiotechsIs Ionis Pharmaceuticals (NASDAQ:IONS) Using Debt Sensibly?March 18, 2024Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
NasdaqGM:URGNBiotechsUroGen Pharma Ltd. (NASDAQ:URGN) Just Released Its Annual Results And Analysts Are Updating Their EstimatesMarch 17, 2024It's been a sad week for UroGen Pharma Ltd. ( NASDAQ:URGN ), who've watched their investment drop 20% to US$14.46 in...
NYSE:ADCTBiotechsADC Therapeutics SA's (NYSE:ADCT) 29% Dip In Price Shows Sentiment Is Matching RevenuesMarch 17, 2024ADC Therapeutics SA ( NYSE:ADCT ) shares have retraced a considerable 29% in the last month, reversing a fair amount of...
NasdaqGM:ADMABiotechsADMA Biologics, Inc.'s (NASDAQ:ADMA) institutional investors lost 5.5% over the past week but have profited from longer-term gainsMarch 16, 2024Key Insights Given the large stake in the stock by institutions, ADMA Biologics' stock price might be vulnerable to...
NasdaqGS:GTHXBiotechsMarket Sentiment Around Loss-Making G1 Therapeutics, Inc. (NASDAQ:GTHX)March 16, 2024With the business potentially at an important milestone, we thought we'd take a closer look at G1 Therapeutics, Inc.'s...
NasdaqGS:SGMOBiotechsAnalysts Have Just Cut Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Revenue Estimates By 24%March 16, 2024Today is shaping up negative for Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ) shareholders, with the analysts delivering...
NasdaqGS:UTHRBiotechsIs United Therapeutics (NASDAQ:UTHR) A Risky Investment?March 15, 2024Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
NasdaqGS:HALOBiotechsHalozyme Therapeutics, Inc. (NASDAQ:HALO) Doing What It Can To Lift SharesMarch 15, 2024With a median price-to-earnings (or "P/E") ratio of close to 16x in the United States, you could be forgiven for...
NasdaqGS:VRTXBiotechsAre Investors Undervaluing Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) By 35%?March 15, 2024Key Insights The projected fair value for Vertex Pharmaceuticals is US$628 based on 2 Stage Free Cash Flow to Equity...
NasdaqGS:EXELBiotechsExelixis Insider Lowered Holding By 28% During Last YearMarch 15, 2024From what we can see, insiders were net sellers in Exelixis, Inc.'s ( NASDAQ:EXEL ) during the past 12 months. That is...
NasdaqGS:VYGRBiotechsThere's No Escaping Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Muted Revenues Despite A 28% Share Price RiseMarch 15, 2024Voyager Therapeutics, Inc. ( NASDAQ:VYGR ) shares have had a really impressive month, gaining 28% after a shaky period...
NasdaqGM:KRTXBiotechsWhen Will Karuna Therapeutics, Inc. (NASDAQ:KRTX) Turn A Profit?March 15, 2024With the business potentially at an important milestone, we thought we'd take a closer look at Karuna Therapeutics...
NasdaqGM:URGNBiotechsUroGen Pharma (NASDAQ:URGN shareholders incur further losses as stock declines 21% this week, taking five-year losses to 61%March 15, 2024Statistically speaking, long term investing is a profitable endeavour. But no-one is immune from buying too high. To...
NasdaqGM:IMRXBiotechsImmuneering Corporation's (NASDAQ:IMRX) latest 57% decline adds to one-year losses, institutional investors may consider drastic measuresMarch 15, 2024Key Insights Institutions' substantial holdings in Immuneering implies that they have significant influence over the...
NasdaqGM:LUMOBiotechsSelling Lumos Pharma Shares at a Lower Price Than Current Market Value May Have Been a Costly Mistake for InsidersMarch 15, 2024Lumos Pharma, Inc.'s (NASDAQ:LUMO) stock price has dropped 13% in the previous week, but insiders who sold US$989k in...
NasdaqCM:HRTXBiotechsHere's What Analysts Are Forecasting For Heron Therapeutics, Inc. (NASDAQ:HRTX) After Its Full-Year ResultsMarch 15, 2024Heron Therapeutics, Inc. ( NASDAQ:HRTX ) investors will be delighted, with the company turning in some strong numbers...
NasdaqGS:AUTLBiotechsAutolus Therapeutics Full Year 2023 Earnings: EPS Misses ExpectationsMarch 15, 2024Autolus Therapeutics ( NASDAQ:AUTL ) Full Year 2023 Results Key Financial Results Net loss: US$208.4m (loss widened by...
NasdaqGS:DYNBiotechsChief Operating Officer Of Dyne Therapeutics Sold 71% Of Their SharesMarch 15, 2024Some Dyne Therapeutics, Inc. ( NASDAQ:DYN ) shareholders may be a little concerned to see that the Chief Operating...
NasdaqGS:BPMCBiotechsDespite shrinking by US$265m in the past week, Blueprint Medicines (NASDAQ:BPMC) shareholders are still up 95% over 1 yearMarch 15, 2024Passive investing in index funds can generate returns that roughly match the overall market. But one can do better than...
NasdaqCM:ALDXBiotechsPainful week for individual investors invested in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) after 28% drop, institutions also suffered lossesMarch 15, 2024Key Insights Aldeyra Therapeutics' significant individual investors ownership suggests that the key decisions are...
NasdaqGS:DSGNBiotechsDesign Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth PlansMarch 15, 2024Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...